Categories
Jump to navigation
Jump to search
The following categories exist on the wiki, and may or may not be unused. Also see wanted categories.
(first | last) View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)- Penile cancer regimens (1 member)
- Peptibody medications (1 member)
- Peptide-drug conjugates (1 member)
- Periampullary adenocarcinoma regimens (2 members)
- Peripheral T-cell lymphoma medications (33 members)
- Peripheral T-cell lymphoma medications (historic) (2 members)
- Peripheral T-cell lymphoma medications (investigational) (1 member)
- Peripheral T-cell lymphoma regimens (2 members)
- Pfizer product (2 members)
- Phenothiazines (3 members)
- Pheochromocytoma medications (4 members)
- Pheochromocytoma regimens (1 member)
- Phosphodiesterase inhibitors (1 member)
- Photosensitizers (4 members)
- Plasma cell dyscrasia medications (5 members)
- Plasma cell dyscrasia regimens (5 members)
- Plasma cell dyscrasias (12 members)
- Plasma cell leukemia medications (6 members)
- Plasma cell leukemia regimens (1 member)
- Plasma cell neoplasm medications (0 members)
- Platinum agents (7 members)
- Polycythemia vera medications (9 members)
- Polycythemia vera regimens (2 members)
- Post-transplant lymphoproliferative disorder medications (12 members)
- Post-transplant lymphoproliferative disorder regimens (1 member)
- Potentiating agents (3 members)
- Primary mediastinal B-cell lymphoma medications (19 members)
- Primary mediastinal B-cell lymphoma regimens (1 member)
- Profibrinolytics (1 member)
- Progestins (2 members)
- Prostate cancer medications (42 members)
- Prostate cancer medications (historic) (8 members)
- Prostate cancer medications (investigational) (4 members)
- Prostate cancer regimens (4 members)
- Proteasome inhibitors (4 members)
- Protein expression-specific medications (47 members)
- Proton pump inhibitors (4 members)
- Purine analogs (9 members)
- Purine analogues (0 members)
- Purine nucleoside phosphorylase (PNP) inhibitors (1 member)
- Pyrimidine analogs (8 members)
- Pyrimidine analogues (0 members)
- Pyruvate kinase activator (1 member)
- Pyruvate kinase deficiency medications (1 member)
- Pyruvate kinase deficiency regimens (1 member)
- RAF1 inhibitors (4 members)
- RANK ligand inhibitors (1 member)
- REMS program (22 members)
- RET inhibitors (11 members)
- RET medications (0 members)
- RET regimens (0 members)
- ROCK2 inhibitors (1 member)
- ROS1 inhibitors (8 members)
- Radiation (5 members)
- Radiation oncology pages (1 member)
- Radioconjugate (3 members)
- Radioimmunoconjugate (2 members)
- Radioimmunotherapeutic (0 members)
- Radiosensitizers (1 member)
- Radiotherapy medications (11 members)
- Recombinant medications (14 members)
- Rectal cancer medications (11 members)
- Rectal cancer regimens (2 members)
- Rectal medications (5 members)
- Regimen index (19 members)
- Renal cell carcinoma medications (28 members)
- Renal cell carcinoma medications (historic) (7 members)
- Renal cell carcinoma medications (investigational) (1 member)
- Renal cell carcinoma regimens (6 members)
- Renal cell carcinomas (6 members)
- Replacement therapy (2 members)
- Retinoids (5 members)
- Rhabdomyosarcoma medications (7 members)
- Rhabdomyosarcoma regimens (1 member)
- Rosai-Dorfman-Destombes disease medications (1 member)
- Rosai-Dorfman-Destombes disease regimens (1 member)
- Routed medications (13 members)
- SMO inhibitors (2 members)
- SMO or PTCH-1 (Hedgehog) medications (0 members)
- SMO or PTCH-1 (Hedgehog) regimens (0 members)
- SPEAR T-cells (1 member)
- SRC inhibitors (8 members)
- STAMP inhibitors (1 member)
- SYK inhibitors (3 members)
- Sarcoma medications (3 members)
- Sarcoma regimens (3 members)
- Sarcomas (2 members)
- Sarcomatoid renal cell carcinoma medications (3 members)
- Sarcomatoid renal cell carcinoma regimens (1 member)
- Second-generation nonsteroidal antiandrogens (4 members)
- Selective estrogen receptor modulators (4 members)
- Selective inhibitors of nuclear export (1 member)
- Serine-threonine kinase inhibitors (12 members)
- Serotonin 5-HT3 antagonists (7 members)
- Sickle cell anemia medications (5 members)
- Sickle cell anemia regimens (2 members)
- Site-agnostic medications (10 members)
- Site-agnostic regimens (17 members)
- Site-specific medications (12 members)
- Site-specific pages (3 members)
- Skin cancer medications (5 members)
- Skin cancer regimens (5 members)
- Skin cancers (10 members)
- Small bowel adenocarcinoma medications (3 members)
- Small bowel carcinoma medications (0 members)
- Small bowel carcinoma regimens (1 member)
- Small cell lung cancer medications (31 members)
- Small cell lung cancer medications (historic) (11 members)
- Small cell lung cancer medications (investigational) (1 member)
- Small cell lung cancer regimens (3 members)
- Small intestine cancer medications (1 member)
- Smoldering multiple myeloma medications (4 members)
- Smoldering multiple myeloma regimens (2 members)
- Soft tissue sarcoma medications (32 members)
- Soft tissue sarcoma medications (historic) (1 member)
- Soft tissue sarcoma medications (investigational) (1 member)
- Soft tissue sarcoma regimens (15 members)
- Soft tissue sarcomas (20 members)
- Solid malignant neoplasm, EGFR-mutated medications (0 members)
- Solid malignant neoplasm, EGFR-mutated regimens (0 members)
- Solid oncology regimens (10 members)
- Soluble decoy receptors (1 member)
- Somatostatin analogs (5 members)
- Statins (2 members)
- Stem cell mobilization regimens (1 member)
- Steroid synthesis inhibitors (3 members)
- Steroidal androgen receptor inhibitors (1 member)
- Steroids (9 members)
- Stub (109 members)
- Subcutaneous medications (71 members)
- Subependymal giant cell astrocytoma medications (1 member)
- Subependymal giant cell astrocytoma regimens (2 members)
- Supportive medications (28 members)
- Supportive oncology (12 members)
- Supportive regimens (0 members)
- Surgery (2 members)
- Synthetic muramyl dipeptides (1 member)
- Systemic mastocytosis medications (8 members)
- Systemic mastocytosis medications (investigational) (1 member)
- Systemic mastocytosis regimens (2 members)
- T-cel leukemia medications (0 members)
- T-cell activators (6 members)
- T-cell acute lymphoblastic leukemia medications (21 members)
- T-cell acute lymphoblastic leukemia medications (investigational) (1 member)
- T-cell acute lymphoblastic leukemia regimens (2 members)
- T-cell leukemia medications (2 members)
- T-cell leukemia regimens (3 members)
- T-cell leukemias (5 members)
- T-cell lymphoma medications (6 members)
- T-cell lymphoma regimens (6 members)
- T-cell lymphomas (12 members)
- T-cell neoplasms (2 members)
- T-cell prolymphocytic leukemia medications (5 members)
- T-cell prolymphocytic leukemia regimens (1 member)
- TEC inhibitors (1 member)
- TEK inhibitors (4 members)
- TGF-beta inhibitors (1 member)
- TG Therapeutics compound (1 member)
- TLR9 agonists (1 member)
- TMB-H medications (0 members)
- TMB-H regimens (0 members)
- TRK inhibitors (4 members)
- TSC1 inhibitors (1 member)
- TSC2 inhibitors (1 member)
- TXK inhibitors (1 member)
- TYK2 inhibitors (1 member)
- Targeted therapeutic (18 members)
- Targeted therapy (0 members)
- Taxanes (5 members)
- Telomerase inhibitors (1 member)
- Tenosynovial giant cell tumor medications (1 member)
- Tenosynovial giant cell tumor regimens (2 members)
- Testicular cancer medications (20 members)
- Testicular cancer medications (historic) (5 members)
- Testicular cancer regimens (2 members)
- Thoracic cancers (4 members)
- Thoracic oncology medications (4 members)
- Thoracic oncology regimens (4 members)
- Thrombocytopenia in liver disease medications (2 members)
- Thrombocytopenia in liver disease regimens (2 members)
- Thrombosis medications (2 members)
- Thrombotic disorders (7 members)
- Thrombotic microangiopathy regimens (1 member)
- Thymoma medications (16 members)
- Thymoma medications (investigational) (1 member)
- Thymoma regimens (1 member)
- Thyroid cancer, differentiated medications (11 members)
- Thyroid cancer, differentiated medications (investigational) (1 member)
- Thyroid cancer, medullary medications (5 members)
- Thyroid cancer medications (11 members)
- Thyroid cancer medications (investigational) (0 members)
- Thyroid cancer regimens (7 members)
- Topical medications (10 members)
- Topoisomerase II inhibitors (16 members)
- Topoisomerase I inhibitors (7 members)
- Topoisomerase inhibitors (2 members)
- Transclusion pages (1 member)
- Transcription factor inhibitors (1 member)
- Transformed lymphoma medications (26 members)
- Transformed lymphoma medications (historic) (1 member)
- Transformed lymphoma regimens (1 member)
- Transplant regimens (3 members)
- Triazenes (3 members)
- Tryptophan hydroxylase inhibitors (1 member)
- Tumor infiltrating lymphocytes (1 member)
- Tumor vaccines (1 member)
- Tyrosine kinase inhibitors (30 members)
- Ultralow molecular weight heparins (1 member)
- Upper tract urothelial carcinoma medications (5 members)
- Upper tract urothelial carcinoma regimens (2 members)
- Urate oxidase (1 member)
- Uric acid lowering agents (2 members)
- Urothelial carcinoma medications (27 members)
- Urothelial carcinoma medications (investigational) (1 member)
- Urothelial carcinoma regimens (5 members)
- Urothelial carcinomas (5 members)
- Uveal melanoma medications (10 members)
- Uveal melanoma regimens (1 member)
- VEGFR inhibitors (22 members)
- Vascular disrupting agents (1 member)
- Vascular sarcoma medications (6 members)
- Vascular sarcoma regimens (3 members)
- Vascular sarcomas (3 members)
- Vasopressin analogs (1 member)
- Venous thromboembolism medications (16 members)
- Venous thromboembolism medications (historic) (2 members)
- Venous thromboembolism regimens (2 members)
- Verastem Oncology compound (1 member)
- Vesicant (22 members)
- Vinca alkaloids (6 members)
- Viral DNA synthesis inhibitors (3 members)
- Vitamin K antagonists (1 member)
- Vulvar cancer medications (2 members)
- Vulvar cancer regimens (1 member)
- WEE1 inhibitors (1 member)
- WHIM syndrome medications (1 member)
- WHIM syndrome regimens (1 member)
- WHO Essential Anti-infective Medicines (11 members)
- WHO Essential Cancer Medicine (79 members)
- WHO Essential Medicines (5 members)
- WHO Essential Pain and Palliative Care Medicine (10 members)
- Waldenström macroglobulinemia medications (29 members)
- Waldenström macroglobulinemia medications (historic) (2 members)
- Waldenström macroglobulinemia regimens (2 members)
- Warm autoimmune hemolytic anemia medications (3 members)
- Warm autoimmune hemolytic anemia regimens (1 member)
- Wilms tumor medications (2 members)
- Wilms tumor regimens (1 member)
- XPO1 inhibitors (1 member)
- Xanthine oxidase inhibitors (1 member)